Avibactam sodium/Ceftazidime hydrate
Pre-clinicalRecruiting 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Infectious Diseases
Conditions
Infectious Diseases
Trial Timeline
Mar 15, 2026 → Mar 30, 2029
NCT ID
NCT06864585About Avibactam sodium/Ceftazidime hydrate
Avibactam sodium/Ceftazidime hydrate is a pre-clinical stage product being developed by Pfizer for Infectious Diseases. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06864585. Target conditions include Infectious Diseases.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06864585 | Pre-clinical | Recruiting |
Competing Products
20 competing products in Infectious Diseases